



US007265215B2

(12) **United States Patent**  
**Kelly et al.**

(10) **Patent No.:** **US 7,265,215 B2**  
(45) **Date of Patent:** **Sep. 4, 2007**

(54) **DNA OR RNA ENCODING A RECOMBINANT DENGUE ENVELOPE PROTEIN**

(75) Inventors: **Eileen P. Kelly**, Takoma Park, MD (US); **Alan D. King**, Washington, DC (US)

(73) Assignee: **United States of America as Represented by the Secretary of the Army**, Washington, DC (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 137 days.

(21) Appl. No.: **10/357,129**

(22) Filed: **Feb. 3, 2003**

(65) **Prior Publication Data**

US 2004/0022811 A1 Feb. 5, 2004

#### **Related U.S. Application Data**

(62) Division of application No. 09/468,517, filed on Dec. 21, 1999, now Pat. No. 6,514,501, which is a division of application No. 08/504,878, filed on Jul. 20, 1995, now Pat. No. 6,074,865.

(51) **Int. Cl.**  
**C07H 21/00** (2006.01)  
**A61K 39/12** (2006.01)

(52) **U.S. Cl.** ..... **536/23.1**; 424/218.1

(58) **Field of Classification Search** ..... 424/218.1, 424/185.1, 186.1, 192.1, 202.1, 204.1; 435/69.3, 435/235.1, 320.1; 536/23.72  
See application file for complete search history.

(56) **References Cited**

#### **U.S. PATENT DOCUMENTS**

5,514,375 A	5/1996	Paoletti et al. ....	424/199.1
6,074,865 A	6/2000	Kelly et al. ....	435/235
6,165,477 A	12/2000	Ivy et al. ....	424/218.1

#### **OTHER PUBLICATIONS**

Hahn et al. Nucleotide sequence of dengue 2 RNA and comparison of the encoded proteins with those of other flaviviruses. *Virology* (1988) vol. 162, No. 1, pp. 167-180.\*

Irie et al. Sequence analysis of cloned dengue virus type 2 genome (New Guinea-C strain). *Gene*. (1989) vol. 75, No. 2, pp. 197-211.\*

Burgess et al. Possible dissociation of the heparin-binding and mitogenic activities of heparin binding growth factor-1 from its receptor-binding activities by site directed mutagenesis of a single lysine residue. *Journal of Cell Biology*. (1990) vol. 111.\*

Lazar et al. Transforming growth factor alpha; mutations of aspartic acid 47 and leucine 48 results in different biological activities. *Molecular and Cellular Biology* (1988) vol. 8, No. 3, p. 1247-1252.\*

Tao et al. Studies of aglycosylated chimeric mouse-human IgG. *The Journal of Immunology* (1989) vol. 143 No. 8, p. 2595-260.\*

Kinney et al. *Intervirology* (2001) 44:176-97.\*

Phillpotts et al. *Archives of Virology* (1996) 141:743-749.\*

Rothman, Alan L. *The Journal of Clinical Investigation* (2004) 113(7):946-951.\*

Putnak et al. Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. *Am. J. Trop. Med. Hyg.* 45: 159-167, 1991.

Delenda et al. Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice. *J. Gen. Virol.* 75: 1569-1578, 1994.

Men et al. Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice. *J. Virol.* 65: 1400-1407, 1991.

Deubel et al. Processing, secretion, and immunoreactivity of carboxy terminally truncated dengue-2 virus envelope proteins expressed in insect cells by recombinant baculovirus. *Virology* 190: 442-447, 1991.

Zhang et al. Immunization of mice with dengue structural proteins and nonstructural protein NS1 expressed by baculovirus recombinant induces resistance to dengue virus encephalitis. *J. Virol.* 62: 3027-3031, 1988.

Eckels et al. Immunization of monkeys with baculovirus-dengue type-4 recombinants containing envelope and nonstructural proteins: evidence of priming and partial protection. *Am. J. Trop. Med. Hyg.* 50: 472-478, 1994.

Green et al., Dengue virus specific human CD4+ T-lymphocyte responses in recipient of an experimental live-attenuated dengue virus typ-1 vaccine. *J. of Virology* (1993)vo. 67, No. 10, pp. 5962-5967.

Feighny et al, Dengue typ-2 virus envelope protein made using recombinant vaculovirus protects mice against virus challenge *American Journal of Tropical Medicine and Hugiene* (1994) vol. 50. No. 3, pp. 322-328.

Markoff et al., Processig of flavivirus structural glycoproteins: stable membrane insertion of premembrane requires the envelope signal peptide. *Virology* (1994) vol. 204, pp. 526-540.

\* cited by examiner

*Primary Examiner*—Stacy B. Chen

(74) *Attorney, Agent, or Firm*—Elizabeth Arwine

(57)

#### **ABSTRACT**

A recombinant protein encompassing the complete envelope glycoprotein and a portion of the carboxy-terminus of the membrane/premembrane protein of dengue 2 virus was expressed in baculovirus as a protein particle. The recombinant protein particle was purified and found to provide protection against lethal challenge with dengue 2 virus in mice.

**9 Claims, 8 Drawing Sheets**